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Abstract
Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Cardiovascular disease (CVD) is
common and a major cause of mortality. Studies on cardiovascular morbidity are abundant, whereas mortality
studies focusing on cardiovascular outcomes are scarce. The aim of this study was to investigate causes of death
and baseline predictors of overall (OM), non-vascular (N-VM), and specifically cardiovascular (CVM) mortality in SLE,
and to evaluate systematic coronary risk evaluation (SCORE).
Methods: 208 SLE patients were included 1995-1999 and followed up after 12 years. Clinical evaluation, CVD risk
factors, and biomarkers were recorded at inclusion. Death certificates and autopsy protocols were collected. Causes
of death were divided into CVM (ischemic vascular and general atherosclerotic diseases), N-VM and death due to
pulmonary hypertension. Predictors of mortality were investigated using multivariable Cox regression. SCORE and
standardized mortality ratio (SMR) were calculated.
Results: During follow-up 42 patients died at mean age of 62 years. SMR 2.4 (CI 1.7-3.0). 48% of deaths were
caused by CVM. SCORE underestimated CVM but not to a significant level. Age, high cystatin C levels and
established arterial disease were the strongest predictors for all- cause mortality. After adjusting for these in
multivariable analyses, only smoking among traditional risk factors, and high soluble vascular cell adhesion
molecule-1 (sVCAM-1), high sensitivity C-reactive protein (hsCRP), anti-beta2 glycoprotein-1 (abeta2GP1) and any
antiphospholipid antibody (aPL) among biomarkers, remained predictive of CVM.
Conclusion: With the exception of smoking, traditional risk factors do not capture the main underlying risk factors
for CVM in SLE. Rather, cystatin C levels, inflammatory and endothelial markers, and antiphospholipid antibodies
(aPL) differentiate patients with favorable versus severe cardiovascular prognosis. Our results suggest that these
new biomarkers are useful in evaluating the future risk of cardiovascular mortality in SLE patients.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
rheumatic disease predominately affecting women (90%).
Clinical manifestations are systemic, affecting organs
including skin, joints, kidneys and the vascular system.
Cardiovascular disease (CVD) is a well studied
co-morbidity of SLE with many remaining questions to
be answered. Both subclinical CVD, measured as
atherosclerosis, and clinical events have been subjects
for investigation. Studies have focused on different
aspects of the disease to find associations with, and to
characterize, SLE-related CVD. For example, CVD in
SLE has been associated with clinical manifestations,
disease activity and damage, traditional and non-
traditional riskfactors, and demographic factors [1-4].
Risk factors for cardiovascular mortality (CVM) in SLE
on the other hand, have not yet been well studied.
In the 1950s, the estimated 5-year survival was less
than 50% [5], but recent studies report 5-year survival of
over 90% [6,7]. Nevertheless, the mortality rate in SLE
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still exceeds that of the general population [8,9]. Death
related to lupus activity and infection has decreased
over time, but still contributes to mortality [10,11], espe-
cially in developing countries[12,13]. However, CVM has
not declined [14] in SLE. A slight increased standardized
mortality ratio (SMR) due to vascular diseases has been
reported [15], and death from CVD accounts for
between 17% and 76% in different studies [16,17]. To
date, most studies have investigated risk factors for
overall mortality (OM), sometimes with diverging results
[10,12,18-21]. As CVM accounts for a growing part of
mortality in SLE, it is important to identify risk factors
specifically for CVM. In the general population, the sys-
tematic coronary risk evaluation (SCORE) [22] is a well-
established tool to predict the 10-year risk of CVM
based on traditional risk factors. SCORE has not pre-
viously been evaluated in SLE. Many new biomarkers
that could help identify underlying molecular pathways
of importance for vascular damage, such as endothelial
and inflammatory markers and cystatin C have not been
evaluated with respect to mortality in SLE.
Therefore, we described a large set of biomarkers and
SCORE in a cohort of 208 SLE patients from a single cen-
ter. We determined causes of death and the contribution
of baseline predictors for OM, CVM and non-vascular
mortality (N-VM).
Materials and methods
During the inclusion period (1995 to 1998), 208 patients
with prevalent disease, who were attending the Depart-
ment of Rheumatology, Karolinska University Hospital,
and fulfilled four or more of the 1982 revised American
College of Rheumatology criteria for classification of SLE
[23] were included. Most patients (94%) were European
Caucasians. The Local Ethics Committee at Karolinska
University Hospital approved the study and patients pro-
vided informed consent.
At inclusion, all data were collected in one session for
each patient. A rheumatologist interviewed and examined
patients according to a structured protocol. Medical his-
tory, traditional CVD risk factors (smoking, hypertension,
hypercholesterolemia, diabetes) and medication were
reviewed, through interviewing the patient and by studying
medical records. SLE disease activity was determined using
the Systemic Lupus Activity Measure (SLAM) [24] and
organ damage was assessed using the Systemic Lupus
International Collaborating Clinics (SLICC) damage index
[25]. Laboratory examinations were performed on fasting
fresh blood samples or on samples stored at -70°C. When
stored samples were used, each analyte was assayed in one
session.
Survival status was followed up in the national popula-
tion registry on March 26, 2010, after a mean time of
12.3 years. Two patients were interviewed by telephone
as they had moved abroad. Death certificates were col-
lected from the Cause of Death Register of The National
Board of Health and Welfare. When available, autopsy
protocols were collected from the department of Pathol-
ogy, Karolinska University Hospital (n = 10), and from
the Department of Forensic Medicine (n = 4). Causes of
death were based on information from death certificates,
autopsy protocols and medical records. Two clinicians
(JG and ES) classified all causes of death together as fol-
lows: CVM (death due to myocardial infarction, athero-
sclerosis, heart failure, ischemic cerebrovascular disease
or sudden death), death due to pulmonary hypertension
(PHT) and N-VM.
Laboratory methods
High sensitivity C-reactive protein (hsCRP), a-1 antitryp-
sin, fibrinogen and serum amyloid A (SAA) were
measured using BN ProSpec System (Dade Behring,
Göttingen, Germany). Complement factors C3 and C4
were analyzed using IMMAGE™ and C3d using an
ARRAY™ system (both instruments from Beckman Coul-
ter, Brea, CA, USA). Apolipoprotein A1, apolipoprotein B,
creatinine, high-density lipoprotein (HDL), low-density
lipoprotein (LDL) and total cholesterol, triglycerides and
urea were analyzed using the LX20 chemistry analyzer
(Beckman Coulter, Brea, CA, USA). Homocysteine was
assayed using the IMx system and Cystatin C was analyzed
using the Architect Ci8200 analyzer (both by Abbott
Laboratories, Chicago IL, USA). ELISA was used to mea-
sure soluble vascular cell adhesion molecule (sVCAM-1)
and IL-6 (DY809 and HS600, R&D Systems, Minneapolis,
MN, USA) and von Willebrand factor (vWF) (antisera
from Dako, Glostrup, Denmark) was calibrated against
Liatest (Diagnostica Stago, Asnières sur Seine, France).
The intra-assay coefficient of variation for the ELISAs
was < 7%.
Antinuclear antibodies (ANA) was analyzed by immuno-
fluorescence on HEp-2 cells (Immunoconcepts, Sacra-
mento, CA, USA) and antibodies to Sjogrens syndrome A
and B (SSA, SSB), Smith antigen (Sm) and Ribonucleopro-
tein (RNP) using ANA-profile ELISA (Thermo Fisher
Scientific, previously Phadia, Uppsala, Sweden), Innolia
immunoblot (Innogenetics, N.U. Ghent, Belgium), and
immunodiffusion (Immunoconcepts, Sacramento, CA,
USA). Anti-dsDNA was determined by Crithidia lucillae
kinetoplast assay (Immunoconcepts, Sacramento, CA,
USA). Anticardiolipin antibodies (aCL) were measured by
ELISA using ethanol-fixed cardiolipin (Sigma-Aldrich,
St Louis, MO, USA) and horseradish peroxidase (HRP)-
conjugated rabbit anti-human IgG and IgM (Dako,
Glostrup, Denmark). Positivity was calibrated against
Harris standard (Louisville, LAPL-GM-001, Louisville, KY,
USA) [26]. Low aCL level corresponded to 10 to 20, med-
ium level to 20 to 80 and high level to > 80 GPU/mPL
Gustafsson et al. Arthritis Research & Therapy 2012, 14:R46
http://arthritis-research.com/content/14/2/R46
Page 2 of 11
units. The cutoff values for positive aCL was calculated to
be at least the 95th percentile of healthy blood donors.
Autoantibodies to b2-glycoprotein1 (ab2GP1, IgG) were
analyzed by ELISA (Orgentec Diagnostika, Mainz,
Germany). Positive cutoff levels were used according to
the manufacturers’ descriptions. Borderline results were
regarded as negative. Lupus anticoagulant (LAC) was
determined using a modified dilute Russell viper venom
method, (Biopool, Umea, Sweden) using Bioclot LAC.
Statistics
Patient characteristics were summarized overall and strati-
fied by outcome using analysis of variance (ANOVA),
Mann-Whitney U-test and Chi2 test, as appropriate.
Skewed continuous variables were log transformed before
use in parametric analyses. The SMR for all deaths and
corresponding 95% confidence interval (CI) assuming a
Poisson distribution was calculated using age-, sex-, and
calendar year-specific mortality rates for the Swedish
population to estimate the expected number of deaths.
Hazard ratios (HRs), it should be hazard ratios everywhere
and 95% CI for OM, CVM and N-VM were calculated in
age-adjusted Cox models for baseline factors. The propor-
tional hazards assumption was evaluated by assessing the
significance of the interaction between predictors and fol-
low-up time and the assumption was met. PHT was
included in OM but otherwise excluded because of too
few cases. The limited number of deaths restricted the
variables in the multivariable-adjusted model to four. The
two predictors most strongly associated with mortality
after age adjustment (in terms of P-value) in the three
groups (OM, CVM, N-VM) were retained in all multivari-
able analyses. Thereafter, each baseline variable was con-
sidered separately in multivariable models.
To evaluate the different multivariable models predicting
CVM in terms of identifying the best model, and to com-
pare that model with SCORE, Akaike information criter-
ion (AIC) values were compared using logistic regression.
To consider the possibility of effect modification by sex,
we stratified by sex; we restricted the sensitivity analysis to
the female subset. Male patients were not considered due
to small sample size. Possible effect modification on cysta-
tin C by steroid treatment was evaluated by stratifying by
steroid treatment. To account for the possibility that sub-
clinical or unregistered nephritis could affect the cystatin
C results, we also stratified by history of nephritis.
SCORE [22] was calculated using the Swedish Heart-
score. Baseline data on age, smoking, sex, systolic blood
pressure and cholesterol were incorporated into the web-
based formula [27]. The 10-year risk of CVM was calcu-
lated for patients between 40 to 65 years of age, according
to the SCORE protocol. The estimated number of CVMs
was compared to the observed number using Fisher´s
exact analysis.
Multiple imputation was used for missing data. For
dichotomous variables the models were re-run assuming
each possible value and the results were compared. For
continuous predictors, three imputed values were used:
the minimum, the mean, and the maximum value.
Descriptive statistics and regression analyses were done
using JMP software (SAS Institute, Carey, North Caro-
lina, USA) and SAS 9.2 was used for SMR calculations.
A P-value ≤ 0.05 was considered statistically significant.
Results
All patients were followed up. Forty-two patients (20%)
died, 36 women and 6 men, at a mean age of 62 years
(women 61 ± SD 14, men 64 ± 19 years). More deaths
were observed than expected (SMR = 2.4, 95% CI 1.7 to
3.0). CVM was the predominant cause of death (n = 20,
48%) (Table 1).
At inclusion, 124 patients were between 40 and 65
years of age. In this group, we observed nine cardiovas-
cular deaths within 10 years. SCORE only predicted four
deaths and the difference was not statistically significant
(odds ratio, OR 2.3, 95% CI 0.7 to 7.8, P = 0.25).
Several parameters measured at baseline differed
between deceased and surviving patients (Table 2) and
persisted after age adjustment for all outcomes. Estab-
lished arterial disease and Cystatin C were the strongest
risk factors in all groups (Table 3) and were retained in
the remaining analyses (Table 4). OM was predicted by
several inflammatory parameters, sVCAM-1 and SLICC
>1.
Smoking was the only traditional risk factor predicting
CVM. sVCAM-1, hsCRP, ab2GP1, any aPL at medium
titer, and baseline warfarin treatment also predicted CVM.
N-VM was positively associated with markers of systemic
inflammation and SLICC >1, while SSB autoantibodies
were inversely associated (Table 4). Results were similar
among women, with a few exceptions (see Table 5). The
best multivariable model predicting CVM included age,
established arterial disease, cystatin C and smoking (AICc
value 77). Yes, the same thing All six multivariable models
predicting CVM (AICc values ranging from 77 to 85) per-
formed better than SCORE (AICc value 122).
Stratification by steroid treatment did not influence
the impact of cystatin C on mortality. Among those
without history of nephritis (n = 135 of whom 25 died
cystatin C adjusted for age remained significant; P =
0.009, RR 4.6 (95% CI 1.5 to 14.5). For patients with his-
tory of nephritis (n = 73 of whom 17 died), the results
for cystatin C were similar; P = 0.001, RR 4.4 (95% CI
1.8 to 10.7).
Results were comparable under the numerous imputed
scenarios with the exception of cyclophosphamide, where
a large proportion of missingness was observed among
deceased patients, and alternative imputed scenarios
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yielded different results. As these were considered unreli-
able, they were removed from consideration.
Discussion
To our knowledge, this is the first study to prospectively
examine risk factors specifically for CVM, which
accounted for almost 50% of deaths in our cohort. Addi-
tionally, 10% of patients died from PHT. CVM and N-VM
shared many risk factors. Established arterial disease,
Cystatin C and inflammatory markers were strong predic-
tors for both, but s-VCAM-1, a marker of endothelial cell
activation, was only associated with CVM. Also, ab2GP1
and any aPL at medium titer predicted CVM. SCORE
underestimated the risk for CVM, but the results were not
statistically significant. Consistent with recently published
work [9,15], SMR was 2.4. Our survival rate of 80% after a
mean follow-up of approximately 12 years is generally
consistent with previous findings, which range from 76%
to 92% survival after 10 years [28,29]. Our results confirm
[6,17,30] that composite damage (SLICC > 1[25]) pre-
dicted OM, but our focus was to analyze the impact of dif-
ferent organ manifestations and immunological profile on
mortality.
High levels of cystatin C and low estimated glomerular
filtration rate (eGFR) based on cystatin C [31] emerged
as strong predictors for all outcomes. These associations
were independent of inflammatory and endothelial bio-
markers and were not modified by steroid treatment at
baseline. Creatinine and eGRF, calculated using the
Modification of Diet in Renal Disease (MDRD) formula
[32] did not predict mortality.
Renal disease in lupus is associated with poor prognosis
[10,20,33]. Cystatin C has been proposed as a more reli-
able biomarker for renal function than creatinine as it
rises with smaller reductions in GFR [34], and is less
influenced by age, sex, muscle mass and diet [35]. Never-
theless, cystatin C levels may be affected by glucocorti-
coid use [36] and inflammation [37], both often present
in SLE. Cystatin C has furthermore emerged as a marker
of CVD risk [38], CVM and N-VM in subjects with nor-
mal eGFR [39]. The fact that the nephritis manifestation
in our study only influenced CVM to a modest degree,
while cystatin C predicted mortality significantly both in
patients with and without reported history of nephritis,
further emphasizes the importance of cystatin C as a new
useful biomarker. Our results demonstrate that cystatin
Table 1 Causes of death in deceased patients (n = 42)




Age at SLE diagnosis,
years
Disease duration at baseline,
years






Non-vascular mortality 18 57 (± 13) 36 (± 13) 15 (± 10)
Infection 5 (12%) 46 (± 12) 20 (± 6.8) 16 (± 10)
Sepsis 3
Pneumonia 1
Perforation of esophagus 1
Bleeding 4 (10%) 56 (± 16) 32 (± 13) 20 (± 9)
Gastrointestinal bleeding 3
Unknown 1
Malignancy 4 (10%) 62 (± 6) 37 (± 10) 18 (± 9)
Lung cancer 2
Colorectal cancer 1
Squamous cell cancer 1
Suicide 2 (5%) 64 (± 3) 51 (± 19) 11 (± 13)
Pulmonary disease
(pneumothorax)
1 (2%) 54 46 6
Renal failure 1 (2%) 85 73 2
Hepatic failure (cirrhosis) 1 (2%) 67 54 2
Pulmonary hypertension 4 (10%) 41 (± 16) 29 (± 13) 10 (± 9)
Total/Average 42 62 (± 14) 33 (± 13) 13 (± 10)
Age is given as mean ± SD.
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Table 2 Baseline characteristics of patients with SLE (n = 208)
All patients n = 208 Deceased patients
n = 42
Surviving patients n = 166 P
Traditional risk factors
Age 47 (35-54) 57 (48-65) 45 (31-52) < 0.0001
Male gender 11% 14% 10%
Smoking 24% 26% 22%
Hypertension 34% 62% 28% < 0.0001
Systolic blood pressure, mmHg 125 (115-140) 140 (123-148) 120 (110-140) 0.001
Hypercholesterolemia 44% 55% 41%
Total cholesterol, (mmol/l) 5.1 (4.3-6.0) 5.6 (4.7-6.7) 5.0 (4.3-5.9) 0.04
Low density lipoprotein mmol/l 2.9 (2.3-3.6) 3.3 (2.2-3.9) 2.8 (2.3-3.6)
High density lipoprotein, mmol/l 1.4 (1.1-1.7) 1.4 (1.1-1.9) 1.4 (1.1-1.7)
Triglycerides, mmol/l* 1.3 (1.0-2.0) 1.7 (1.2-2.5) 1.2 (0.9-1.9) 0.004
ApolipoproteinB/ApolipoproteinA*# 0.5 (0.3-0.6) 0.5 (0.3-0.8) 0.5 (0.3-0.6)
Diabetes 3% 10% 2% 0.03
Established arterial disease 13% 40% 5% <0.0001
SCORE 3.2% (± 2.8) 4.4% (± 2.4) 2.7% (± 2.4) 0.005
Lupus manifestations (ever present)§
Age at disease onset, years 30 (22-40) 35 (25-52) 28 (21-40) 0.0002
Disease duration, years 12 (5-20) 13.5 (6-26) 12 (5-19) 0.008
Malar rash 56% 50% 58%
Discoid rash 20% 12% 21%
Photosensitivity 71% 60% 73%
Oral ulcers 28% 28% 26%
Arthritis 86% 86% 86%
Pleuritis 40% 52% 37%
Pericarditis 18% 17% 19%
Nephritis 35% 40% 34%
Neurological disorder 15% 29% 12% 0.009
Leucopenia 51% 37% 55% 0.04
Thrombocytopenia 22% 30% 20%
Previous venous occlusion 11% 17% 9%
SLICC > 1 [25] 59% 93% 50% < 0.0001
SLAM > 6 [24] 59% 73% 55% 0.03
Autoantibodies against
(at baseline if not stated otherwise)
Double-stranded DNA 38% 43% 36%
Double-stranded DNA (ever) 61% 64% 60%
Cardiolipin IgG low titer 48% 50% 47%
Cardiolipin IgG medium titer 18% 31% 15% 0.02
Cardiolipin IgM low titer 16% 19% 15%
Cardiolipin IgM medium titer 8% 14% 6%
beta2glykoprotein-1# 22% 31% 20%
Lupus anticoagulant 23% 31% 21%
Any antiphospholipid low titer¶ 60% 62% 60%
Any antiphospholipid medium titer¶ 39% 55% 36% 0.03
Sjogrens syndrome A 41% 21% 46% 0.003
Sjogrens syndrome B 22% 10% 25%
Smith 10% 7% 10%
Ribonucleoprotein 19% 21% 19%
Medication
Steroids 51% 48% 62%
Cyclofosfamid (ever use) 17% 26% 16%
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C is strongly predictive of mortality and that it merits
further evaluation as a biomarker in SLE.
sVCAM-1 was a strong risk factor for OM and in par-
ticular for CVM, underscoring the importance of
endothelial activation for CVM in lupus. Endothelial
biomarkers have not previously been investigated in the
context of mortality in SLE. Levels of sVCAM-1 are ele-
vated in SLE patients with manifest CVD [40] and
together with vWf, another endothelial marker, they
predicted the first arterial event [26]. An association
with atherosclerosis has been demonstrated both in the
general population and in lupus [4].
Systemic inflammation is associated with CVD, CVM
and N-VM in the general population [41,42] and may
be associated with CVD in lupus [26,43-45], although
the impact on mortality has not yet been well studied.
We demonstrated that several inflammatory markers
were associated with all-cause mortality. For CVM,
hsCRP (and a1-antitrypsin among women) had the
greatest impact.
ab2GP1 and any aPL at medium titer were associated
with CVM in multivariable analyses. This observation is
in accordance with previous studies, where aPLs were
associated with cardiovascular events [26,44]. The high
prevalence of aCL in our study is probably due to a low
cutoff for positivity at our laboratory in the mid 90’s,
when baseline data were collected. Since then, much
work has been carried out to evaluate more appropriate
cutoffs for aCL in relation to what is clinically signifi-
cant [46]. When we used a cutoff at medium titer, the
prevalence of aCL was more in accordance with other
studies [47]. Furthermore, medium titer of aPLs were
Table 2 Baseline characteristics of patients with SLE (n = 208) (Continued)
Azathioprine 12% 12% 12%
Chloroquine/hydroxychloroquine 27% 14% 30% 0.04
Warfarin 13% 29% 10% 0.001
Acetylsalicylic acid 21% 33% 18% 0.02
Statins 2% 5% 1% 0.05
Methotrexate 4% 7% 1%
Cyclosporine 3% 10% 1% 0.004
Inflammatory markers
High sensitivity C reactive protein, mg/l* # 2.2 (0.8-6.2) 5.1 (2.2-12.1) 1.8 (0.7-4.5) 0.0002
Fibrinogen, g/l* # 3.7 (2.9-4.6) 4.3 (3.5-5.2) 3.4 (2.9-4.4) < 0.0001
a-1 antitrypsine, g/l # 1.5 (1.3-1.8) 1.7 (1.5-2.1) 1.5 (1.3-1.7) 0.0001
Serum amyloid A, mg/l* # 5.4 (2.7-12) 10.5 (5.9-21.6) 4.7 (2.4-9.6)
Interleukin-6, ng/l* # 3.5 (2.1-7.0) 5.2 (2.9-9.7) 3.1 (2.0-6.2)
Complement factor 3, g/l # 1.0 ( 0.8-1.2) 1.0 (0.7-1.3) 1.0 (0.8-1.2)
Complement factor 3 degradation products, mg/l* # 11.9 (9.6-14.9) 13.4 (10.8-16.6) 11.6 (9.5-14.5) 0.02
Complement factor 4 (g/l)* # 0.2 (0.1-0.2) 0.2 (0.1-0.2) 0.2 (0.1-0.2)
Endothelial markers
Soluble vascular cell adhesion molecule 1, ng/l* # 315 (258-392) 377 (297-526) 306 (250-375) < 0.0001
Von Willebrand factor, %*# 120 (63-175) 144 (102-231) 116 (60-164) 0.003
Markers of renal damage
Creatinine 82 (73-95) 91 (75-138) 81 (73-92) < 0.0001
Modification of Diet in Renal Disease formula, ml/min/1.73m2 66.6 (54.3-79.1) 54.6 (36.6-76.9) 67.7 (59.5-79.9) 0.0005
Cystatin C GFR 80 (61-107) 55 (27-83) 86 (71-114) < 0.0001
Cystatin C, mg/l* 1.0 (0.8-1.2) 1.3 (1.0-2.2) 0.9 (0.8-1.1) < 0.0001
Blod urea nitrogen, mmol/l* # 5.8 (4.7-7.3) 7.3 (6.1-13.6) 5.5 (4.5-6.7)
Pathologic urine 24% 22% 29%
Other biomarkers
Homocysteine, mol/l* # 12.5 (10.1-16.5) 14.3 (10.8-20.6) 12 (10.0-15.3) 0.002
Distributions are given as % or median (interquartile range), except for SCORE, where mean values are given. P-values ≤ 0.05 are presented. *Variables with non-
normal distribution. # Analysis of frozen samples. §According to American College of Rheumatology (ACR) criteria [23]. ¶Positive antibody against cardiolipin IgG/
IgM at low and medium titer, respectively, beta2glykoprotein-1, or a positive lupus anticoagulant test. Hypertension, systolic blood pressure > 140 mm Hg and/or
diastolic blood pressure > 90 mmHg and/or treatment for hypertension; hypercholesterolemia, total cholesterol level > 5.2 mmol/L; established arterial disease,
history of myocardial infarction, angina pectoris, ischemic cerebrovascular disease, ischemic peripheral arterial disease at baseline; SCORE, systematic coronary risk
evaluation calculated on 124 patients 40 to 65 years old; SLICC, systemic lupus international collaborating clinics; pathologic urine, as defined by the systemic
lupus activity measure (SLAM). Data were missing as follows (deceased/survivors): low and high density lipoprotein (5/11), triglycerides (0/1), Apolipoprotein B/
Apolipoprotein A (1/0), leucopenia (1/0), thrombocytopenia (1/3), cyclophosphamide ever (15/3), statins (0/3), cyklosporin (0/1), a-1 antitrypsine (0/1), serum
amyloid (1/4), complement factor (C)3 (0/3), C3 degradation products (0/3), C 4 (0/3), soluble vascular cell adhesion molecule 1 (1/2), von Willebrand factor (1/2),
cystatin C/cystatin C glomerular filtration rate (GFR) (1/0), urea (3/3), homocysteine (2/5).
Gustafsson et al. Arthritis Research & Therapy 2012, 14:R46
http://arthritis-research.com/content/14/2/R46
Page 6 of 11
Table 3 Age-adjusted Cox regression analysis
OM
n = 42





















Triglycerides, mmol/l† 0.02 1.9
(1.1-3.3)
0.04 2.5 (1.1-5.7)







Nephritis 0.03 3.0 (1.2-7.9)










SLAM > 6 [24] 0.02 2.1
(1.1-4.5)
Autoantibodies against
Double-stranded DNA 0.05 1.9
(1.0-3.6)
0.02 3.1 (1.2-8.3)
Cardiolipin IgG low titer 0.03 2.9 (1.1-8.1)
Cardiolipin IgG medium titer 0.006 2.7
(1.4-5.3)
0.04 3.2 (1.1-8.5) 0.02 3.6 (1.3-9.6)
beta2glykoprotein-1 0.04 2.9 (1.0-7.8)
Any aPL medium titer ¶ 0.02 2.1
(1.1-3.9)
0.03 2.8 (1.1-7.7) 0.03 2.8 (1.1-7.6)
Sjogrens syndrome A 0.01 0.4
(0.2-0.8)
Sjogrens syndrome B 0.04 0.4
(0.1-0.9)















Fibrinogen, g/l† 0.0002 9.5 (3.0-31) 0.02 10.2
(1.6-70)
0.0005 19.9 (3.8-110)












Von Willebrand factor, %† 0.009 1.9
(1.2-3.0)
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predictive of CVM, indicating that these are more clini-
cally relevant levels. However, we have previously
demonstrated that aPL only at a low cutoff were predic-
tive of the first arterial event [26]. ab2GP1 was analyzed
later on frozen samples, with the method currently used
at our immunological laboratory. Taken together, our
results demonstrate that clinically relevant levels for aPL
need to be further studied and standardized. Studies in
our research group are ongoing to investigate these
issues.
SSA/SSB antibodies often occur together with skin
manifestations in SLE. We noted an inverse association
between positivity for SSB antibodies and N-VM. SSA
antibodies [20] and photosensitivity [10] were previously
inversely linked to mortality. Together these results indi-
cate that lupus patients with SSA/SSB positivity and/or
skin manifestations have a better prognosis, further
illustrating that sub-phenotypes of SLE have differen-
tiated risk profiles [26].
Smoking was the only traditional CVD risk factor
associated with CVM in multivariable analyses. Smok-
ing has previously been shown to predict cardiovascu-
lar events in SLE [26,44]. Hypertension was predictive
of mortality in earlier SLE studies [19,48]. As defini-
tions differ and antihypertensive agents are used in the
treatment of nephritis, even in the absence of high
blood pressure, it is nowadays difficult to assess its
contribution to mortality. Hyperlipidemia was not an
important risk factor for mortality in multivariable
analyses.
SCORE is a widespread clinical cardiovascular risk
scoring system distributed through the European Society
of Cardiology. SCORE underestimated CVM among our
SLE patients (nine observed vs. four predicted cases),
but the difference was not significant. This is neverthe-
less interesting as it suggests that optimal preventive
cardiovascular strategies in lupus need to target other
factors in addition to traditional CVD risk factors.
Table 3 Age-adjusted Cox regression analysis (Continued)
Markers of renal damage
Cystatin C GFR < 0.0001 0.4
(0.2-0.5)
0.001 0.3 (0.2-0.6) 0.0002 0.3 (0.2-0.5)
Cystatin C† < 0.0001 4.4
(2.4-7.9)







Urea, mmol/l† 0.01 2.1 (1.2-3.2) 0.02 2.3 (1.1-4.0)
Pathologic urine 0.04 2.2 (1.0-4.4) 0.04 3.5 (1.1-8.1)
Only variables with P-values ≤ 0.05 in either group are presented. Calculations were done using age-adjusted Cox regression. †Calculations on log transformed
values. Any aPL¶, any antiphospholipid antibody, positive antibody against cardiolipin IgG/IgM at medium titer, beta2glykoprotein-1 or a positive lupus
anticoagulant test. Hypertension, systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mmHg and/or treatment for hypertension;
hypercholesterolemia, total cholesterol level > 5.2 mmol/L; established arterial disease, history of myocardial infarction, angina pectoris, ischemic cerebrovascular
disease, ischemic peripheral arterial disease at baseline; SCORE, systematic coronary risk evaluation calculated on 124 patients 40 to 65 years old; SLICC, systemic
lupus international collaborating clinics; pathologic urine, as defined by the systemic lupus activity measure (SLAM); OM, overall mortality; CVM, cardiovascular
mortality; N-VM, non-vascular mortality. HR, hazard ratio
Table 4 Multivariable Cox regression model adjusted for age, arterial disease and cystatin C (208 patients).
OM CVM N-VM
P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI)
Smoking 0.02 3.4 (1.3-9.2)
SLICC>1[25] 0.008 4.1 (1.4-17.3) 0.05 5.6 (1.0-103.6)
ab2GP1 0.03 3.4 (1.2-9.7)
Any aPL medium titer 0.05 2.8 (1.0-8.2)
Sjogrens syndrome B antibodies 0.02 1.3e-6 (0-0.7)
Warfarin 0.05 3.4 (1.0-10.4)
High sensitivity CRP 0.04 1.3 (1.0-1.6) 0.02 1.6 (1.1-2.3)
Fibrinogen 0.04 3.7 (1.0-13.1) 0.05 6.7 (1.0-45.4)
a-1-antitrypsine 0.007 2.7 (1.3-5.2) 0.004 4.3 (1.6-10.7)
Soluble vascular cell adhesion molecule 1 0.05 2.7 (1.0-6.7) 0.02 5.3 (1.3-19.3)
ab2GP1, anti-b2 glycoprotein-1; any aPL, any antiphospholipid; positive antibody against cardiolipin IgG/IgM at medium titer, b2GP1 or a positive lupus
anticoagulant test; OM, overall mortality; CVM, cardiovascular mortality; HR, hazard ratio; N-VM, non-vascular mortality; SLICC, systemic lupus international
collaborating clinics. Age, arterial disease and cystatin C were included in all multivariable models. Each variable that was significant in age-adjusted Cox
regression (Table 3) for OM, CVM and N-VM, was included one by one, together with the three above-mentioned variables, creating a model with four variables.
The table presents the results of the significant associations. Only variables that have P-values ≤ 0.05 in either group are presented. In this way, five different
multivariable models are presented for OM, six for CVM, and four for N-VM, respectively.
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Notably, four SLE patients (10%) in this cohort died
from PHT. They died at a young mean age (41 years).
Death from PHT was 15% in a Korean cohort [49], but
in most studies PHT is not reported as a prominent
cause of death.
Detailed baseline information and complete follow-up
are strengths of this study. Assigning a principle cause of
death is difficult, particularly in patients with chronic dis-
eases with numerous co-morbidities. We did not rely on
death certificates only, but supplemented these data with
autopsy protocols and medical charts, thus using all avail-
able sources to determine a main cause of death. Because
national mortality data are based solely on international
classification of diseases (ICD) codes, derived from only
one of the data sources we considered in the determina-
tion of cause of death, cause-specific SMRs could not be
calculated. It is difficult to compare causes of death in our
cohort and in the general population for the same reason.
The majority of our patients were female, and of Eur-
opean Caucasian origin. Because Swedish healthcare is
tax-funded, granting universal access, patients with lower
socioeconomic status have the same access with the same
threshold maximum payment per year. Therefore further
studies in male patients, other ethnic cohorts and socioe-
conomic groups are needed. Furthermore, we had limited
statistical power. For example, only 13 deaths occurred
among patients aged 50 years or younger, prohibiting the
evaluation of effect modification by age. Another limita-
tion of this study is the assessment of risk factors at base-
line only, which makes it difficult to evaluate development
of disease manifestations and other events during follow-
up. Finally, we did not adjust for multiple comparisons,
and therefore P-values close to 0.05 should be interpreted
with caution.
Conclusions
This study demonstrates that high levels of cystatin C
strongly predicted all cause mortality. Additionally,
CVM was associated with high levels of sVCAM-1,
hsCRP and aPL, demonstrating that systemic and vascu-
lar inflammation, and prothrombotic autoantibodies are
important risk factors for CVM. With the exception of
smoking, traditional risk factors had less impact. Thus,
new biomarkers differentiate SLE patients with favorable
vs. more severe prognosis.
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